Tarceva can be given as a single agent after failure of first-line or second-line chemotherapy
for non-small
cell lung cancer. However, Tarceva works best for certain subsets of patients: Asians, women, non-smokers, and those with adenocarcinoma histology. This drug still has been found to benefit males, smokers, and those with squamous cell histology, but to a lesser extent.